These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29369973)

  • 41. Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation.
    Peddi VR; Wiseman A; Chavin K; Slakey D
    Transplant Rev (Orlando); 2013 Oct; 27(4):97-107. PubMed ID: 23932018
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Everolimus and sirolimus in transplantation-related but different.
    Klawitter J; Nashan B; Christians U
    Expert Opin Drug Saf; 2015 Jul; 14(7):1055-70. PubMed ID: 25912929
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?
    El-Chemaly S; Goldberg HJ; Glanville AR
    Expert Rev Respir Med; 2014 Dec; 8(6):657-60. PubMed ID: 25199529
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection?
    Burra P; Buda A; Livi U; Rigotti P; Zanus G; Calabrese F; Caforio A; Menin C; Canova D; Farinati F; Luciana Aversa SM
    Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1065-70. PubMed ID: 16957512
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.
    Gabardi S; Baroletti SA
    Pharmacotherapy; 2010 Oct; 30(10):1044-56. PubMed ID: 20874042
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Conversion from calcineurin inhibitors to mTOR inhibitors as primary immunosuppressive drugs in pediatric heart transplantation.
    Asante-Korang A; Carapellucci J; Krasnopero D; Doyle A; Brown B; Amankwah E
    Clin Transplant; 2017 Oct; 31(10):. PubMed ID: 28708333
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential expression of p-mTOR in cutaneous basal and squamous cell carcinomas likely explains their different response to mTOR inhibitors in organ-transplant recipients.
    Karayannopoulou G; Euvrard S; Kanitakis J
    Anticancer Res; 2013 Sep; 33(9):3711-4. PubMed ID: 24023300
    [TBL] [Abstract][Full Text] [Related]  

  • 48. mTOR as a therapeutic target in patients with gastric cancer.
    Al-Batran SE; Ducreux M; Ohtsu A
    Int J Cancer; 2012 Feb; 130(3):491-6. PubMed ID: 21898386
    [TBL] [Abstract][Full Text] [Related]  

  • 49. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
    Grzybowska-Izydorczyk O; Smolewski P
    Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rapamycin and everolimus facilitate hepatitis E virus replication: revealing a basal defense mechanism of PI3K-PKB-mTOR pathway.
    Zhou X; Wang Y; Metselaar HJ; Janssen HL; Peppelenbosch MP; Pan Q
    J Hepatol; 2014 Oct; 61(4):746-54. PubMed ID: 24859454
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Current and future directions in mammalian target of rapamycin inhibitors development.
    Fasolo A; Sessa C
    Expert Opin Investig Drugs; 2011 Mar; 20(3):381-94. PubMed ID: 21299441
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Renal function preservation with the mTOR inhibitor, Everolimus, after lung transplant.
    Schneer S; Kramer MR; Fox B; Rusanov V; Fruchter O; Rosengarten D; Bakal I; Medalion B; Raviv Y
    Clin Transplant; 2014 Jun; 28(6):662-8. PubMed ID: 24738962
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
    Wüthrich RP; Kistler AD; Serra AL
    Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience.
    Errasti P; Izquierdo D; Martín P; Errasti M; Slon F; Romero A; Lavilla FJ
    Transplant Proc; 2010 Oct; 42(8):3053-4. PubMed ID: 20970608
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment with everolimus is associated with a procoagulant state.
    Baas MC; Gerdes VE; Ten Berge IJ; Heutinck KM; Florquin S; Meijers JC; Bemelman FJ
    Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature.
    Nashan B; Citterio F
    Transplantation; 2012 Sep; 94(6):547-61. PubMed ID: 22941182
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside.
    Vincenzi B; Napolitano A; D'Onofrio L; Frezza AM; Silletta M; Venditti O; Santini D; Tonini G
    Expert Opin Investig Drugs; 2011 Dec; 20(12):1685-705. PubMed ID: 22010859
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of mTOR inhibitors in the management of posttransplant malignancy.
    Monaco AP
    Transplantation; 2009 Jan; 87(2):157-63. PubMed ID: 19155967
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
    Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunosuppressive minimization with mTOR inhibitors and belatacept.
    Diekmann F
    Transpl Int; 2015 Aug; 28(8):921-7. PubMed ID: 25959589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.